Imagen Technologies has raised more than $100 million in growth capital, the AI-enabled radiology company announced on November 18, 2026. Alongside the new capital, Imagen secured rights to up to 150 million additional imaging studies across X-ray, CT, MRI and ultrasound that it plans to use to train and validate its diagnostic AI models. Investors in the round include Casdin Capital, Threshold and Kli Capital, though the company did not name a formal lead investor or disclose a valuation.
Unlike pure software vendors, Imagen sells radiology interpretation as a managed service. It employs more than 230 board-certified radiologists and cardiologists who read over 2 million imaging studies a year across more than 28 states, backed by the company's own FDA-cleared AI tools.
What Imagen builds and how it is growing
Imagen's pitch is that AI should make radiologists' jobs better, not just faster. Its platform combines clinical workflow software with AI-assisted triage and detection tools that flag findings for physician review. The company says its radiologist headcount roughly doubled year over year, a sign that its staffing model of recruiting physicians directly, rather than licensing software to hospital radiology groups, is scaling.
"The greatest opportunity for AI in radiology isn't simply to make physicians faster. It's to give them better tools to deliver exceptional patient care," said Chief Medical Information Officer Serge Sicular, according to the Imagen newsroom. Associate Chief Medical Officer Laurence Eckel added that top radiologists "want more than a place to read studies. They want a practice that values their expertise."
Why the imaging-rights deal matters
The most unusual part of this raise isn't the dollar figure, it's the data. Securing rights to 150 million additional studies gives Imagen a training set that dwarfs what most AI-imaging startups can access, since radiology AI quality depends heavily on volume and diversity of labeled scans. That data advantage, paired with a captive pool of physicians who both generate and validate labels, is the moat Imagen is building against software-only rivals.
Competitors and the AI-imaging landscape
Imagen competes with a growing field of AI-diagnostics companies, from large PACS and imaging-AI vendors to startups selling point solutions for specific pathologies like stroke or lung nodules. Most of those competitors sell software licenses into hospital radiology departments. Imagen's service-plus-software model is closer to a staffing and technology hybrid, which lets it capture both interpretation revenue and AI training data from the same patient encounters.
What to watch next
Imagen has not disclosed its valuation or total funding to date, which will likely surface if the company pursues a larger round or IPO process. Expect the company to publish validation data on the new models trained from its expanded imaging library, and to continue expanding its radiologist network into new states as a way of both growing revenue and feeding its AI pipeline.